PMLiVE7d
Merck and Astellas/Pfizer’s bladder cancer combination receives MHRA approval
Keytruda (pembrolizumab) and Astellas/Pfizer’s Padcev (enfortumab vedotin) have been approved by the Medicines and Healthcare ...
PMLiVE7d
Roche’s Itovebi combination granted FDA approval for advanced breast cancer
Roche’s PI3K inhibitor Itovebi (inavolisib) has been approved by the US Food and Drug Administration (FDA) as part of a ...
PMLiVE11d
AbbVie shares promising late-stage results for Parkinson’s disease candidate tavapadon
AbbVie has shared positive top-line results from a late-stage study of its investigational Parkinson’s disease (PD) drug in adults. The phase 3 TEMPO-1 trial evaluated two fixed doses of the D1/D5 ...
PMLiVE18d
MHRA approves Pharming’s Joenja as first drug for rare immune disease APDS
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pharming Group’s Joenja (leniolisib) to treat patients with the rare immune disease activated phosphoinositide 3-kinase ...
PMLiVE15d
GSK receives CHMP recommendation for meningococcal disease vaccine Menveo
GSK has received a recommendation from the European Medicines Agency’s human medicines committee for a single-vial, fully liquid presentation of its meningococcal vaccine Menveo. The new presentation, ...
PMLiVE17d
Roche’s injectable C5 inhibitor PiaSky recommended by NICE for rare blood disorder PNH
Roche’s injectable component C5 inhibitor has been recommended by the National Institute for Health and Care Excellence (NICE) to treat the rare blood disorder paroxysmal nocturnal haemoglobinuria ...
PMLiVE17d
Johnson & Johnson’s Yuvanci granted EC approval to treat pulmonary arterial hypertension
Johnson & Johnson’s (J&J) Yuvanci (single tablet combination therapy [STCT] of macitentan and tadalafi) has been approved by the European Commission (EC) as a long-term treatment for pulmonary ...
PMLiVE15d
Results from Global Pharmaceutical Customer Experience survey
Research on the state of the customer experience (CX) that the global pharmaceutical industry provides to healthcare professionals (HCPs) has been released by DT Consulting, an Indegene company. For ...
PMLiVE21d
FDA grants rare paediatric disease designation to Enterprise’s cystic fibrosis candidate
The US Food and Drug Administration (FDA) has granted rare paediatric disease (RPD) designation to Enterprise Therapeutics’ investigational cystic fibrosis therapy. Estimated to affect more than ...
PMLiVE24d
Sanofi/Regeneron’s Dupixent recommended by CHMP for younger eosinophilic oesophagitis patients
Sanofi and Regeneron’s Dupixent (dupilumab) has been recommended by the European Medicines Agency’s human medicines committee to treat younger eosinophilic oesophagitis (EoE) patients. The Committee ...
PMLiVE21d
UCB shares positive two-year results for Bimzelx in hidradenitis suppurativa
UCB has shared positive two-year results for its inflammatory disease drug Bimzelx (bimekizumab) in moderate-to-severe hidradenitis suppurativa (HS). New data from the phase 3 BE HEARD I and BE HEARD ...
PMLiVE17d
‘Causes That Count, Health’ report – key issues affecting global health
Public health, access to healthcare services, and food and nutrition are some of the most important issues facing people around the world. So, earlier this year, purpose consultancy Revolt launched ...